We also demonstrate that RNASE4 inhibition decreases prostate cancer growth in vitro and in vivo, underscoring a therapeutic potential of RNASE4 inhibitors in prostate cancer treatment. This evidence concerns the gene RNASE4 and prostate carcinoma.